TOKYO (JAPAN) – US President Donald Trump said that Japan’s Fujifilm Holdings Corp’s facility in Texas, USA, has been awarded a contract worth $265 million (206.15 million pounds) to enhance production of a coronavirus vaccine candidate.
He made the announcement on Monday while touring a Fujifilm facility in North Carolina. This widens the ambit of the pact between the Department of Health and Human Services, Texas A&M university system and Fujifilm Diosynth Biotechnologies.
Fujifilm said in a release that the funds will expedite the expansion at the Texas facility in College Station.
Fujifilm Diosynth, which is a pharmaceutical ingredient subsidiary of the Japanese firm, announced last week that it would make bulk drug substances for Novavax Inc.’s vaccine candidate, NVX-CoV2373.
The firm also said that it would spend $928 million to double capacity at a facility in Denmark engaged in seeking ways to treat the virus.
(Photos syndicated via Reuters)
This story has been edited by BH staff and is published from a syndicated field